
JY-2
CAS No. 339103-05-8
JY-2( —— )
Catalog No. M36546 CAS No. 339103-05-8
JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 45 | Get Quote |
![]() ![]() |
10MG | 76 | Get Quote |
![]() ![]() |
25MG | 150 | Get Quote |
![]() ![]() |
50MG | 227 | Get Quote |
![]() ![]() |
100MG | 335 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameJY-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionJY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.
-
DescriptionJY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity.
-
In VitroReal Time qPCRCell Line:HepG2 and INS-1 cells Concentration:10, 50 and 100 μM Incubation Time:24 h Result:Reduced palmitic acid (PA)-induced G6Pase and PEPCK mRNA expression. Inhibited PA-induced lipid accumulation. Reduced PA-induced mRNA expression of ER stress markers (ATF3, CHOP and GRP78).Western Blot Analysis Cell Line:HepG2 cells Concentration:10, 50 and 100 μM Incubation Time:4 h; in the presence of PA (500μM)Result:Increased p-FoxO1 levels in the whole cell lysate with a concurrent reduction in nuclear FoxO1 levels.
-
In VivoAnimal Model:C57BL/6J mice Dosage:50, 100, 200 mg/kg Administration:Oral, three times for two days (9:00 AM, 7:00 PM, 9:00 AM on the next day)Result:Improved glucose tolerance. Significantly reduced the expression of G6Pase and PEPCK mRNA in the liver. Enhanced mRNA expression of insulin and PDX-1 in the pancreas.Animal Model:db/db mice and C57BL/6J mice, high fat-diet-induced obese diabetic (DIO) model Dosage:50, 100 mg/kg Administration:Oral, once daily for 4 weeks Result:Decreased the levels of fasting blood glucose, improved glucose tolerance. The expression of ColIV, a fibrosis marker, was also lowered.Animal Model:C57BL/6J mice Dosage:20 mg/kg or 50 mg/kg Administration:IV or PO (Pharmacokinetic Analysis) Result:Showed an overall good pharmacokinetic profile.
-
Synonyms——
-
PathwayNuclear Receptor/Transcription Factor
-
TargetFoxo1
-
RecptorFOXO1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339103-05-8
-
Formula Weight292.12
-
Molecular FormulaC13H7Cl2N3O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (427.91 mM; Ultrasonic (<60°C)
-
SMILESClC1=CC(Cl)=C(C=C1)C1=NC(=NO1)C1=NC=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Choi HE, et al. Novel FoxO1 inhibitor, JY-2, ameliorates palmitic acid-induced lipotoxicity and gluconeogenesis in a murine model. Eur J Pharmacol. 2021 May 15;899:174011.?
molnova catalog



related products
-
AS-1842856
A novel transcription factor Foxo1 inhibitor that potently and selectively inhibits Foxo1-mediated transactivation with IC50 of 33 nM.
-
JY-2
JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.
-
FOXO1-IN-8
A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.